Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
49.96
-0.56 (-1.11%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High
September 02, 2024
Rebounding growth could make shares of this leading drugmaker a big winner.
Via
The Motley Fool
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now
September 01, 2024
No stock is perfect, but quality businesses can stand the test of time in your portfolio.
Via
The Motley Fool
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
September 01, 2024
From
Bristol Myers Squibb
Via
Business Wire
Market Whales and Their Recent Bets on BMY Options
August 27, 2024
Via
Benzinga
Key Takeaways From Bristol-Myers Squibb Analyst Ratings
August 22, 2024
Via
Benzinga
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
August 21, 2024
Via
Benzinga
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
August 30, 2024
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
August 30, 2024
The Benzinga Stock Whisper Index looks at five stocks seeing above average interest from investors during the week.
Via
Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
August 28, 2024
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose.
Via
Benzinga
Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday
August 28, 2024
Via
Benzinga
Check Out What Whales Are Doing With BMY
August 16, 2024
Via
Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
August 28, 2024
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial.
Via
Investor's Business Daily
3 High-Yield Dividend Stocks With Payout Ratios Below 75%
August 28, 2024
Unlock steady income and growth potential with these high-yield, low-risk dividend powerhouses.
Via
The Motley Fool
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
August 28, 2024
These underappreciated dividend payers offer yields above 4% at recent prices.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
August 27, 2024
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports.
Via
Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
August 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
August 26, 2024
From
Bristol Myers Squibb
Via
Business Wire
Cancer Medicines From Merck, Bristol Myers And BeiGene In Question, As FDA Committee To Discuss Limiting PD-1 Drugs For Stomach Cancer
August 23, 2024
The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors for advanced gastric, gastroesophageal junction adenocarcinoma, and...
Via
Benzinga
Exposures
Product Safety
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
August 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
August 20, 2024
With yields above 4%, these stocks could do a lot to boost your passive income stream
Via
The Motley Fool
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
August 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Where Will Bristol Myers Squibb Be in 5 Years?
August 18, 2024
The drugmaker will go through key changes by the end of the decade.
Via
The Motley Fool
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
August 18, 2024
ETFs offer a good way to own a diversified portfolio of income-producing equities.
Via
The Motley Fool
Topics
ETFs
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
August 15, 2024
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
August 14, 2024
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction.
Via
Benzinga
Topics
Workforce
Exposures
Layoff
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
August 13, 2024
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and...
Via
Benzinga
The 3 Best Healthcare Stocks to Buy in August 2024
August 12, 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Via
InvestorPlace
Bristol-Myers Squibb Co: Is It A Buy?
August 11, 2024
As part of an ongoing series, we typically conduct an analysis on one of the companies in our screens each week. This week, we thought we’d take a look at one of the cheapest stocks in our screens:...
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
...
62
63
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.